Literature DB >> 20209603

Determination of immune memory to hepatitis B vaccination through early booster response in college students.

Chyi-Feng Jan1, Kuo-Chin Huang, Yin-Chu Chien, Donald E Greydanus, H Dele Davies, Tai-Yuan Chiu, Li-Min Huang, Chien-Jen Chen, Ding-Shinn Chen.   

Abstract

UNLABELLED: The long-term protection of hepatitis B (HB) vaccination has been debated for years. The purpose here was to evaluate the kinetic changes of antibody to HB surface antigen (anti-HBs) and define immune memory of the HB vaccine among college students who had previously received full neonatal immunization against HB. In all, 127 college students aged 18-23 years born after July 1984 who had completed HB vaccination and were seronegative for all three HB viral markers, including HB surface antigen (HBsAg), antibody to HB core protein (anti-HBc), and anti-HBs, were recruited. They received three doses of HB vaccine at enrollment, 1 month and 6 months after enrollment. Their anti-HBs titers were assayed at enrollment, 7-10 days, 1 month, 6 months, and 7 months following the first dose of HB vaccine. The anti-HBs seroprotective rates for subjects 7-10 days, 1 month, 6 months, and 7 months postvaccination were 20.5%, 75.6%, 94.5%, and 99.2%, respectively. Those who were seroprotective at 7 to 10 days after one dose of HB vaccine booster developed significantly higher levels of anti-HBs at 1 and 6 months than those not developing seroprotective anti-HBs response at an earlier timepoint.
CONCLUSION: At least one-quarter of HB vaccinees have lost their immune memory to the HB vaccine when entering college. Immune memory to HB vaccine was identified by early seroconversion, which was present in only 20% of vaccinees in the present study. To ensure higher than 90% anti-HBs seroconversion rates, at least 2 doses of HB booster vaccines are recommended for at-risk youths who received complete HB vaccinations in neonatal or infant periods but are seronegative for HBsAg, anti-HBs, and anti-HBc in adolescence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20209603     DOI: 10.1002/hep.23543

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  32 in total

1.  Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine.

Authors:  Vladimir Gilca; Gaston De Serres; Nicole Boulianne; Donald Murphy; Manale Ouakki; Phillipe De Wals; Gisele Trudeau; Richard Massé; Marc Dionne
Journal:  Hum Vaccin Immunother       Date:  2013-06-06       Impact factor: 3.452

2.  Persistence of immunity 18-19 years after vaccination against hepatitis B in 2 cohorts of vaccinees primed as infants or as adolescents in Italy.

Authors:  Luisa Romanò; Cristina Galli; Catia Tagliacarne; Maria Elena Tosti; Claudio Velati; Laura Fomiatti; Maria Chironna; Rosa Cristina Coppola; Mario Cuccia; Rossana Mangione; Fosca Marrone; Francesco Saverio Negrone; Antonino Parlato; Carla Maria Zotti; Alfonso Mele; Alessandro Remo Zanetti
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

3.  Seroprevalence of hepatitis B and immune response to hepatitis B vaccination in Chinese college students mainly from the rural areas of western China and born before HBV vaccination integrated into expanded program of immunization.

Authors:  Xue-Yan Liao; Zhen-Zuo Zhou; Fu-Bang Wei; Han-Ning Qin; Yuan Ling; Rong-Cheng Li; Yan-Ping Li; Yi Nong; Kui-Xia Sun; Jie Li; Hui Zhuang
Journal:  Hum Vaccin Immunother       Date:  2013-09-09       Impact factor: 3.452

4.  Infectious diseases and immunological responses in adult subjects with lifetime untreated, congenital GH deficiency.

Authors:  Viviane C Campos; Mônica R Barrios; Roberto Salvatori; Roque Pacheco de Almeida; Enaldo V de Melo; Ana C S Nascimento; Amélia Ribeiro de Jesus; Manuel H Aguiar-Oliveira
Journal:  Endocrine       Date:  2016-08-03       Impact factor: 3.633

5.  Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China.

Authors:  Zhen-Zi Wang; Yu-Hua Gao; Wei Lu; Cun-Duo Jin; Ying Zeng; Ling Yan; Feng Ding; Tong Li; Xue-En Liu; Hui Zhuang
Journal:  Hum Vaccin Immunother       Date:  2016-11-22       Impact factor: 3.452

Review 6.  Unsolved problems and future perspectives of hepatitis B virus vaccination.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

7.  Persistence of protection of hepatitis B vaccine and response to booster immunization in 2- to 12-year-old children.

Authors:  Cenk Aypak; Adnan Yüce; Hülya Yıkılkan; Süleyman Görpelioğlu
Journal:  Eur J Pediatr       Date:  2012-08-16       Impact factor: 3.183

8.  Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization.

Authors:  Shunshun Lu; Jingjing Ren; Qian Li; Zhenggang Jiang; Yongdi Chen; Kaijin Xu; Bing Ruan; Shigui Yang; Tiansheng Xie; Linna Yang; Jing Li; Jun Yao
Journal:  Hum Vaccin Immunother       Date:  2016-12-01       Impact factor: 3.452

9.  HLA-DPB1 and anti-HBs titer kinetics in hepatitis B booster recipients who completed primary hepatitis B vaccination during infancy.

Authors:  T-W Wu; C-C Chu; H-W Chang Liao; S-K Lin; T-Y Ho; M Lin; H H Lin; L-Y Wang
Journal:  Genes Immun       Date:  2013-11-28       Impact factor: 2.676

Review 10.  Hepatitis B virus: where do we stand and what is the next step for eradication?

Authors:  Haruki Komatsu
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.